Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Alnylam Pharmaceuticals, Inc., Halozyme Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Alnylam Pharmaceuticals, Inc., Halozyme Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Alnylam Pharmaceuticals, Inc., Halozyme Therapeutics and Inc.

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer’s disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington’s disease; ALN-5288 for Alzheimer’s disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson’s disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Latest Biotechnology and Alnylam Pharmaceuticals, Inc., Halozyme Therapeutics, Inc. Stock News

As of August 6, 2026, Alnylam Pharmaceuticals, Inc. had a $28.9 billion market capitalization, compared to the Biotechnology median of $269.0 million. Alnylam Pharmaceuticals, Inc.’s stock is down 45.8% in 2026, up 5% in the previous five trading days and down 48.41% in the past year.

Currently, Alnylam Pharmaceuticals, Inc.’s price-earnings ratio is 38.5. Alnylam Pharmaceuticals, Inc.’s trailing 12-month revenue is $4.8 billion with a 16.1% net profit margin. Year-over-year quarterly sales growth most recently was 66.8%. Analysts expect adjusted earnings to reach $8.934 per share for the current fiscal year. Alnylam Pharmaceuticals, Inc. does not currently pay a dividend.

As of August 6, 2026, Halozyme Therapeutics, Inc. had a $10.2 billion market cap, putting it in the 77th percentile of all stocks. Halozyme Therapeutics, Inc.’s stock is up 49.1% in 2026, up 21.6% in the previous five trading days and up 41.03% in the past year.

Currently, Halozyme Therapeutics, Inc.’s price-earnings ratio is 30.2. Halozyme Therapeutics, Inc.’s trailing 12-month revenue is $1.5 billion with a 23.1% net profit margin. Year-over-year quarterly sales growth most recently was 42.2%. Analysts expect adjusted earnings to reach $8.100 per share for the current fiscal year. Halozyme Therapeutics, Inc. does not currently pay a dividend.

How We Compare Alnylam Pharmaceuticals, Inc., Halozyme Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Alnylam Pharmaceuticals, Inc., Halozyme Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Alnylam Pharmaceuticals, Inc., Halozyme Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
Alnylam Pharmaceuticals, Inc.	ALNY	F
Halozyme Therapeutics, Inc.	HALO	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Alnylam Pharmaceuticals, Inc. has a Value Score of 8, which is Ultra Expensive. Halozyme Therapeutics, Inc. has a Value Score of 34, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Alnylam Pharmaceuticals, Inc., Halozyme Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Alnylam Pharmaceuticals, Inc., Halozyme Therapeutics or Inc. is the better investment when it comes to value.

Alnylam Pharmaceuticals, Inc., Halozyme Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Alnylam Pharmaceuticals, Inc.	ALNY	D
Halozyme Therapeutics, Inc.	HALO	B

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Alnylam Pharmaceuticals, Inc. has a Growth Score of 32, which is Weak. Halozyme Therapeutics, Inc. has a Growth Score of 69, which is Strong.

The Growth Grade Winner: Halozyme Therapeutics, Inc.

As you can clearly see from the Growth Grade breakdown above, Halozyme Therapeutics, Inc. has a more attractive growth grade than Alnylam Pharmaceuticals, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, Halozyme Therapeutics, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Alnylam Pharmaceuticals, Inc., Halozyme Therapeutics and Inc.’s Quality Grades

Company	Ticker	Quality
Alnylam Pharmaceuticals, Inc.	ALNY	A
Halozyme Therapeutics, Inc.	HALO	A

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Alnylam Pharmaceuticals, Inc. has a Quality Score of 87, which is Very Strong. Halozyme Therapeutics, Inc. has a Quality Score of 95, which is Very Strong.

The Quality Grade Winner: It’s a Tie!

Looking at the Quality Grade breakdown above, both Alnylam Pharmaceuticals, Inc., Halozyme Therapeutics and Inc. have a grade of A. For investors who focus solely on a company’s overall quality, you will need to conduct further research into both companies to see if they are a good fit for your portfolio. As a good rule of thumb, you should always analyze multiple factors based on a wide range of metrics before choosing a company to invest in.

Other Alnylam Pharmaceuticals, Inc., Halozyme Therapeutics and Inc. Grades

In addition to Value, Growth and Quality, A+ Investor also provides grades for Momentum and Estimate Revisions.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Alnylam Pharmaceuticals, Inc., Halozyme Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Alnylam Pharmaceuticals, Inc., Halozyme Therapeutics or Inc. Stock?

Overall, Alnylam Pharmaceuticals, Inc. stock has a Value Score of 8, Growth Score of 32 and Quality Score of 87.

Halozyme Therapeutics, Inc. stock has a Value Score of 34, Growth Score of 69 and Quality Score of 95.

Comparing Alnylam Pharmaceuticals, Inc., Halozyme Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.